Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism
- 1 January 2006
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (1) , 37-42
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Cardiac innervation and clinical correlates in idiopathic Parkinsonʼs diseaseNuclear Medicine Communications, 2003
- [123I] Meta-iodobenzylguanidine Myocardial Scintigraphy Differentiates Corticohasal Degeneration from Parkinson's Disease.Internal Medicine, 2003
- Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Significant reduction of 125I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinsonʼs diseaseNuclear Medicine Communications, 2002
- Differentiating Parkinson Disease From Multiple-System Atrophy by Measuring Cardiac Iodine-123 Metaiodobenzylguanidine AccumulationJAMA, 2000
- Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinsonʼs diseaseNuclear Medicine Communications, 1998
- Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehydehyde or diethyldithiocarbamateNeurochemistry International, 1992
- MPTP mechanisms of neurotoxicity and their implications for Parkinson's diseaseEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983